Strongyloidiasis is an infection with the soil-transmitted roundworm Strongyloides stercoralis, and ivermectin is its established, FDA-approved treatment. Unlike some of the drug's more controversial off-label uses in recent years, this is not a matter of dispute among infectious-disease specialists: ivermectin is the preferred first-line therapy, supported by randomized controlled trials and recommended by the CDC and the World Health Organization. This article lays out what the evidence actually shows, how dosing works, what a realistic recovery timeline looks like, and why this particular parasite requires more careful follow-up than most.

Why Strongyloides Is a Different Kind of Parasite

Strongyloides stercoralis enters the body when larvae in contaminated soil penetrate the skin, usually through bare feet. From there they migrate through the bloodstream to the lungs, are coughed up and swallowed, and mature into adult worms in the small intestine. What sets this parasite apart from other intestinal worms is a peculiar and medically important trick: it can complete its entire life cycle inside a single host, without ever leaving the body. Larvae produced in the gut can re-penetrate the intestinal wall or the skin around the anus and reinfect the same person indefinitely. This "autoinfection" cycle means a person infected decades earlier, perhaps during military service, missionary work, or childhood in a tropical region, can still be carrying live worms today, often with no symptoms beyond intermittent bloating, rash, or unexplained eosinophilia on a blood count.

The stakes rise sharply if the immune system is later suppressed, whether by corticosteroids, chemotherapy, organ transplantation, or HTLV-1 infection. In that setting, the autoinfection cycle can spiral out of control into hyperinfection syndrome, with massive worm burdens spreading to the lungs, bloodstream, and even the central nervous system. This complication carries a high mortality rate if unrecognized, which is precisely why the ability to reliably eradicate a quiet, long-standing infection matters. It is a sober reminder that the body's defenses, remarkably designed as they are, depend on an intact immune system to keep even a small, persistent invader in check.

The Evidence Behind Ivermectin as First-Line Therapy

Ivermectin's role here is not a recent or experimental idea. It was approved by the FDA for intestinal strongyloidiasis in the 1990s, building on earlier work establishing its efficacy against the parasite. The drug itself has a notable origin story: it was derived from avermectins, compounds produced by Streptomyces avermitilis, a bacterium isolated from a soil sample near a golf course in Japan by microbiologist Satoshi Ōmura. Working with parasitologist William Campbell at Merck, this soil-derived compound was developed into one of the most effective antiparasitic drugs in history, work recognized with the Nobel Prize in Physiology or Medicine in 2015. It is a fitting example of how much benefit to human health has come from ordinary, created things in the natural world, studied carefully and put to use.

The clinical evidence for treating strongyloidiasis specifically is solid. A systematic review published in the Cochrane Database of Systematic Reviews (2016), which pooled data from multiple randomized controlled trials, found that ivermectin achieved higher parasitological cure rates than albendazole, another antiparasitic commonly used for intestinal worms. Individual trials comparing single-dose ivermectin against albendazole have reported cure rates for ivermectin generally in the 80s to mid-90s percent range, compared to considerably lower rates for albendazole, often below 65 percent in the same studies. Ivermectin performed comparably to thiabendazole, an older drug once used for the same purpose, but with far fewer side effects; thiabendazole frequently caused nausea, dizziness, and vomiting severe enough that patients discontinued treatment, and it has largely fallen out of use for this reason.

This body of evidence is what places ivermectin ahead of alternatives in every major treatment guideline for uncomplicated strongyloidiasis. It is worth being direct about the distinction: this is a well-established, evidence-backed indication, quite unlike some other applications of the drug that have circulated in public discussion without comparable trial support. Readers should not conflate the two.

Dosing: What the Tablet Strength Actually Means

Ivermectin tablets sold for human use are commonly manufactured in 3 milligram strength. The correct dose of ivermectin is not a fixed number of milligrams but is calculated by body weight, at 200 micrograms per kilogram (0.2 mg/kg), taken as a single oral dose on an empty stomach with water. In practice, this means the number of tablets a person takes depends on how much they weigh. A person weighing around 60 kilograms (roughly 130 pounds) would need about 12 milligrams total, which works out to four of the 3 milligram tablets, taken together as one dose. There is no separate "12 mg version" or "3 mg version" of the drug for strongyloidiasis; these are simply tablet strengths and multiples used to reach the correct weight-based amount. A pharmacist or physician calculates the exact number of tablets for each patient.

For uncomplicated intestinal strongyloidiasis, many treatment protocols use this single weight-based dose. Because of the parasite's autoinfection cycle, however, some guidelines, including CDC treatment recommendations, favor giving a second identical dose two weeks after the first, to catch any larvae that were in an early stage of development and not yet susceptible at the time of the first dose. This two-dose approach is particularly favored for chronic infections identified well after initial exposure.

What to Expect: Timeline and Confirming the Infection Is Gone

Ivermectin acts quickly against the worm itself. It binds to glutamate-gated chloride channels found in invertebrate nerve and muscle cells, channels that do not exist in the same form in humans, causing paralysis and death of the parasite within the intestine. Most patients notice improvement in gastrointestinal symptoms, when present, within several days to two weeks. However, "feeling better" is not the same as being cured, and this is a parasite where confirming clearance genuinely matters given the risk of silent, decades-long persistence.

Because no single test is perfect, physicians often use a combination of stool testing, symptom resolution, and trending laboratory values over several months before declaring the infection resolved, rather than relying on how a patient feels in the first week or two.

Special Situations: Hyperinfection and Higher-Risk Patients

For most otherwise healthy adults, standard weight-based dosing is sufficient. Hyperinfection syndrome and disseminated strongyloidiasis are different matters entirely and require more intensive management, generally in a hospital setting. Treatment protocols for hyperinfection typically involve daily ivermectin dosing, sometimes combined with albendazole, continued until stool and sputum samples are clear of larvae for at least two consecutive weeks, given how much larger the worm burden and how impaired the immune response can be in these patients.

A practical complication arises when a critically ill patient cannot reliably absorb oral medication because of severe intestinal disease or ileus. In these cases, case reports and small case series in the medical literature describe the use of a subcutaneous, veterinary-formulated ivermectin preparation under compassionate use, administered by physicians in a hospital setting when oral or rectal routes are not viable. This is an off-label, exceptional use restricted to severe hyperinfection under direct medical supervision, not a substitute for approved oral dosing in ordinary care, and it should never be attempted outside a hospital setting.

Anyone starting corticosteroids or other immunosuppressive therapy who has a history of residence in a region where strongyloidiasis is common, or who has unexplained eosinophilia, should raise this history with their physician before treatment begins, since screening and pre-emptive treatment can prevent a dangerous downstream complication. This is exactly the kind of situation where an informed patient, working proactively with their own doctor rather than waiting to be asked, can materially change the outcome for themselves or a family member.

Ivermectin is generally well tolerated. Reported side effects are usually mild and include dizziness, nausea, and itching. Safety data in pregnancy are limited, and current guidance generally favors deferring treatment of uncomplicated infection until after delivery unless the potential benefit clearly outweighs the uncertainty, a decision that should be made individually with an obstetric provider. Dosing in young children depends on body weight and is generally avoided below a weight threshold set by regulatory labeling, again a matter for direct physician guidance rather than self-determination.

Key takeaway: For strongyloidiasis, ivermectin is a genuinely well-evidenced, FDA-approved first-line treatment given as a correctly calculated weight-based dose, and its success should be confirmed through follow-up stool testing and monitoring over months, not judged by symptoms alone.